4-(4-硝基苯基)哌啶-2,6-二酮 | 954124-21-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-(4-硝基苯基)哌啶-2,6-二酮
• 英文名称: 4-(4-nitrophenyl)piperidine-2,6-dione
• CAS: 954124-21-1
• 化学式: C₁₁H₁₀N₂O₄
• 分子量: 234.211
• InChiKey: CLNUBVHQUXBQSK-UHFFFAOYSA-N

物化性质

• 熔点：
  241-243 °C(Solv: ethanol (64-17-5))
• 沸点：
  484.5±45.0 °C(Predicted)
• 密度：
  1.365±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  92
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2925190090

反应信息

• 作为反应物：
  描述：

  4-(4-硝基苯基)哌啶-2,6-二酮 在 钯 甲醇 作用下， 以 甲醇 为溶剂， 25.0 ℃ 、18.38 MPa 条件下， 反应 5.0h， 以to afford 106 mg (62%) of the title compound as an off-white solid的产率得到4-(4-amino-phenyl)-piperidine-2,6-dione
  参考文献：
  名称：

  INHIBITORS OF C-FMS KINASE

  摘要：

  本发明涉及公式I的化合物：其中Z，X，J，R2和W在规范中列出，以及其溶剂化物，水合物，互变异构体和药学上可接受的盐，其抑制蛋白酪氨酸激酶，特别是c-fms激酶。本发明还提供了使用公式I的化合物治疗自身免疫性疾病和具有炎症成分的疾病；治疗卵巢癌，子宫癌，乳腺癌，前列腺癌，肺癌，结肠癌，胃癌，毛细胞白血病引起的转移；以及治疗疼痛，包括由肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏，炎症和神经源性疼痛；以及骨质疏松症，Paget病和其他骨吸收介导的疾病，包括类风湿性关节炎和其他形式的炎症性关节炎，骨关节炎，假体失效，骨溶性肉瘤，骨髓瘤和转移至骨骼的肿瘤。

  公开号：

  US20150051196A1
• 作为产物：
  描述：

  3-(4-硝基苯基)戊二酸 在 乙酰氯 、 尿素 作用下， 反应 4.33h， 生成 4-(4-硝基苯基)哌啶-2,6-二酮
  参考文献：
  名称：

  假肽胍-胍催化前手性三酰基胺的对映选择性去对称化

  摘要：

  已经在不对称有机催化中探索了具有C s对称性的三酰基胺，从而在具有弱配位阴离子的手性假肽胍-胍盐的催化下通过甲醇分解开发了一种新的催化对映选择性去对称化前手性三酰基胺。这种有机催化方法为合成有用的具有 1,5-二羰基部分的手性酰亚胺酯提供了一种有效的方法，其合成潜力已在两种 GABA 类似药物的不对称合成中得到体现，( R )-巴氯芬·HCl 和 ( S )-普瑞巴林。

  DOI：

  10.1021/acs.orglett.2c02785

文献信息

• INHIBITORS OF C-FMS KINASE
  申请人：Illig Carl R.

  公开号：US20070249593A1

  公开（公告）日：2007-10-25

  The invention is directed to compounds of Formula I: wherein Z, X, J, R 2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

  本发明涉及式I化合物：其中Z、X、J、R2和W在说明书中规定，以及抑制蛋白酪氨酸激酶，尤其是c-fms激酶的溶剂化物、水合物、互变异构体和药用盐。治疗自身免疫病；和治疗具有炎症成分的疾病；治疗来自卵巢癌、子宫癌、乳腺癌、前列腺癌、肺癌、结肠癌、胃癌、毛细胞白血病的转移；和治疗疼痛，包括由肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏、炎症性和神经性疼痛；以及骨质疏松症、佩吉特病，以及骨吸收介导病状的其它疾病，包括类风湿性关节炎、其它形式的炎症性关节炎、骨关节炎、假体失败、溶骨肉瘤、骨髓瘤和骨转移瘤，也提供了式I化合物。
• Novel 4-phenylpiperidine-2,6-dione derivatives. Ligands for α1-adrenoceptor subtypes
  作者：Giuseppe Romeo、Luisa Materia、Maria N. Modica、Valeria Pittalà、Loredana Salerno、Maria A. Siracusa、Fabrizio Manetti、Maurizio Botta、Kenneth P. Minneman

  DOI：10.1016/j.ejmech.2011.03.054

  日期：2011.7

  ligands for the α1-adrenergic receptor (α1-AR) subtypes. Some synthesized compounds, tested in binding assays for the human cloned α1A-, α1B-, and α1D-AR subtypes, displayed affinities in the nanomolar range. Highest affinity values were found in derivatives having a butyl connecting chain between the 4-phenylpiperidine-2,6-dione and the phenylpiperazinyl moieties. 1-[4-[4-(2-Methoxyphenyl)piperaz

  在1-位轴承的ω-一些新的4-苯基哌啶-2,6-二酮[4-（取代的苯基）哌嗪-1-基]烷基部分，设计并合成作为配体为α 1 -肾上腺素能受体（α 1 -AR）亚型。一些合成的化合物，在用于人的克隆α结合测定中测试1A - ，α 1B -和α 1D -AR亚型，在纳摩尔范围内显示的亲和力。在具有在4-苯基哌啶-2，6-二酮和苯基哌嗪基部分之间的丁基连接链的衍生物中发现最高的亲和力值。1- [4- [4-（2-甲氧基苯基）哌嗪-1-基]丁基] -4-苯基哌啶-2,6-二酮（34）对α1A -AR（pķ我 = 8.74）和10倍的选择性相比于其他两个α 1 -AR亚型。一些有代表性的化合物还以评估其对耦合到α信号转导途径影响进行测试1个-AR亚型。它们都阻断了去甲肾上腺素诱导的肌醇磷脂水解的刺激作用，因此表现为拮抗剂。结合数据，用于完善对α先前开发的药效模型1D -ARs。修订后的模型显示了高度
• Inhibitors of C-FMS Kinase
  申请人：Illig Carl R.

  公开号：US20080275031A1

  公开（公告）日：2008-11-06

  The invention is directed to compounds of Formula I: wherein Z, X, J, R 2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

  本发明涉及公式I的化合物：其中Z，X，J，R2和W在规范中设置，以及其溶剂化物，水合物，互变异构体和药学上可接受的盐，该化合物抑制蛋白酪氨酸激酶，特别是c-fms激酶。本发明还提供了使用公式I化合物治疗自身免疫性疾病和具有炎症成分的疾病的方法；治疗卵巢癌，子宫癌，乳腺癌，前列腺癌，肺癌，结肠癌，胃癌，毛细胞白血病的转移；以及治疗疼痛，包括由肿瘤转移或骨关节炎引起的骨骼疼痛，或脏器，炎症和神经源性疼痛；以及骨质疏松症，帕吉特氏病和其他骨吸收介导发病率的疾病，包括类风湿性关节炎和其他形式的炎性关节炎，骨关节炎，假体失败，骨溶性肉瘤，骨髓瘤和肿瘤转移至骨骼的公式I化合物。
• Inhibitors of c-fms kinase
  申请人：Janssen Pharmaceutica, N.V.

  公开号：US07414050B2

  公开（公告）日：2008-08-19

  The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

  本发明涉及一类式I的化合物：其中Z、X、J、R2和W在规范中列出，以及其溶剂化物、水合物、互变异构体和药学上可接受的盐，该化合物抑制蛋白酪氨酸激酶，特别是c-fms激酶。本发明还提供了使用式I化合物治疗自身免疫性疾病和具有炎症成分的疾病；治疗卵巢癌、子宫癌、乳腺癌、前列腺癌、肺癌、结肠癌、胃癌、毛细胞白血病引起的转移；以及治疗疼痛，包括肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏、炎症和神经性疼痛；以及骨质疏松症、帕吉特病和其他骨吸收介导的疾病，包括类风湿性关节炎和其他形式的炎症性关节炎、骨关节炎、假体失效、骨溶性肉瘤、骨髓瘤和转移至骨骼的肿瘤。
• Inhibitors of C-FMS kinase
  申请人：Janssen Pharmaceutica, N.V.

  公开号：US07973035B2

  公开（公告）日：2011-07-05

  The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

  本发明涉及式I的化合物：其中Z、X、J、R2和W在规范中列出，以及其溶剂化物、水合物、互变异构体和药学上可接受的盐，其抑制蛋白酪氨酸激酶，尤其是c-fms激酶。本发明还提供了使用式I化合物治疗自身免疫性疾病和带有炎症成分的疾病的方法；治疗卵巢癌、子宫癌、乳腺癌、前列腺癌、肺癌、结肠癌、胃癌、毛细胞白血病的转移；以及治疗疼痛，包括肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏、炎症和神经源性疼痛；以及骨质疏松症、帕吉特病和其他骨吸收介导的疾病，包括类风湿性关节炎和其他形式的炎症性关节炎、骨关节炎、假体失效、骨溶性肉瘤、骨髓瘤和转移至骨骼的肿瘤。